KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Shares Outstanding (2016 - 2025)

Fulgent Genetics' Shares Outstanding history spans 3 years, with the latest figure at $30.9 million for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 1.04% year-over-year to $30.9 million; the TTM value through Sep 2025 reached $30.9 million, up 1.04%, while the annual FY2024 figure was $30.8 million, 4.01% up from the prior year.
  • Shares Outstanding for Q3 2025 was $30.9 million at Fulgent Genetics, up from $30.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $30.9 million in Q3 2025 and bottomed at $29.7 million in Q4 2023.
  • The 3-year median for Shares Outstanding is $30.6 million (2024), against an average of $30.4 million.
  • The largest annual shift saw Shares Outstanding increased 4.01% in 2024 before it increased 1.04% in 2025.
  • A 3-year view of Shares Outstanding shows it stood at $29.7 million in 2023, then increased by 4.01% to $30.8 million in 2024, then rose by 0.04% to $30.9 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Shares Outstanding are $30.9 million (Q3 2025), $30.6 million (Q2 2025), and $30.6 million (Q1 2025).